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ARTICLE
Elevated circulating follistatin associates with an
increased risk of type 2 diabetes
Chuanyan Wu1,2,3,23, Yan Borné1,23, Rui Gao2, Maykel López Rodriguez4,5, William C. Roell6,
Jonathan M. Wilson 6, Ajit Regmi6, Cheng Luan1, Dina Mansour Aly1, Andreas Peter7,8,9,
Jürgen Machann 8,9,10, Harald Staiger7,8,9, Andreas Fritsche7,8,9, Andreas L. Birkenfeld 7,8,9, Rongya Tao11,
Robert Wagner 7,8,9, Mickaël Canouil 12, Mun-Gwan Hong 13,24, Jochen M. Schwenk 13,24,
Emma Ahlqvist 1, Minna U. Kaikkonen 5, Peter Nilsson 1, Angela C. Shore 14, Faisel Khan15,
Andrea Natali16, Olle Melander1, Marju Orho-Melander1, Jan Nilsson 1, Hans-Ulrich Häring7,8,9, Erik Renström1,
Claes B. Wollheim1,17, Gunnar Engström1, Jianping Weng18, Ewan R. Pearson19,24, Paul W. Franks 1,24,
Morris F. White11, Kevin L. Duffin6, Allan Arthur Vaag20, Markku Laakso 4,21, Norbert Stefan 7,8,9,
Leif Groop 1,22 & Yang De Marinis 1,2,18✉
The hepatokine follistatin is elevated in patients with type 2 diabetes (T2D) and promotes
hyperglycemia in mice. Here we explore the relationship of plasma follistatin levels with
incident T2D and mechanisms involved. Adjusted hazard ratio (HR) per standard deviation
(SD) increase in follistatin levels for T2D is 1.24 (CI: 1.04–1.47, p < 0.05) during 19-year
follow-up (n= 4060, Sweden); and 1.31 (CI: 1.09–1.58, p < 0.01) during 4-year follow-up
(n= 883, Finland). High circulating follistatin associates with adipose tissue insulin resistance
and non-alcoholic fatty liver disease (n= 210, Germany). In human adipocytes, follistatin
dose-dependently increases free fatty acid release. In genome-wide association study
(GWAS), variation in the glucokinase regulatory protein gene (GCKR) associates with plasma
follistatin levels (n= 4239, Sweden; n= 885, UK, Italy and Sweden) and GCKR regulates
follistatin secretion in hepatocytes in vitro. Our findings suggest that GCKR regulates fol-
listatin secretion and that elevated circulating follistatin associates with an increased risk of
T2D by inducing adipose tissue insulin resistance.
https://doi.org/10.1038/s41467-021-26536-w OPEN
A full list of author affiliations appears at the end of the paper.









Follistatin is a secreted protein that is expressed in almost alltissues. It is linked to metabolic diseases1,2, with elevatedplasma levels in patients with type 2 diabetes (T2D)1. Evi-
dence suggests that follistatin has multiple auto- and paracrine
functions in various tissues. Follistatin binds and neutralizes
TGF-β family members3. Follistatin is essential for the formation
and growth of muscle fibers4,5 and is involved in the development
of muscle fiber hypertrophy6–11. Furthermore, follistatin was
found to enhance thermogenic gene expression in differentiated
mouse brown adipocytes12. Short-term follistatin treatment
reduced glucagon secretion from islets of Langerhans, whereas
long-term follistatin treatment prevented apoptosis and induced
proliferation of rat β cells13. Local overexpression of follistatin in
the pancreas from diabetic mice resulted in increased serum
insulin levels14. In humans, circulating follistatin derives pre-
dominately from the liver and its expression and secretion are
upregulated by a high glucagon-to-insulin ratio13.
In mice15, follistatin was identified as a mediator of diabetes by
promoting white adipose tissue insulin resistance. In hypergly-
cemic and high-fat-fed obese mice, disruption of follistatin
restored glucose tolerance, white adipose tissue insulin signaling
and suppression of hepatic glucose production by insulin. In
obese individuals with diabetes who underwent gastric bypass
surgery, serum follistatin decreased in parallel with HbA1c
levels15. Circulating follistatin levels were also found to be
increased in individuals with T2D, associating positively with
HbA1c and fasting blood glucose levels. However, follistatin is
unaffected by acute alterations in blood glucose and blood insulin
concentrations during an oral glucose tolerance test (OGTT)1. So
far it is unknown whether elevation of plasma follistatin associ-
ates with the risk of T2D, independently of established diabetes
risk markers. Furthermore, it needs to be established whether and
to what extent genetics explains the variability of circulating
follistatin levels and whether the mechanisms of follistatin to
induce insulin resistance in mice may also be operative in
humans.
In this work, we show that circulating follistatin associates with
an increased risk of T2D, independently of established risk fac-
tors. A possible mechanism may involve an effect of follistatin to
induce adipose tissue insulin resistance, resulting in increased
adipocyte free fatty acid (FFA) release, which also promotes
nonalcoholic fatty liver disease (NAFLD). Secretion of follistatin
from the liver cells is regulated by GCKR, in addition to insulin
and glucagon.
Results
Plasma follistatin levels associate with the risk of T2D. We
evaluated the association of circulating follistatin levels at baseline
with incident T2D in the Malmö Diet and Cancer Cardiovascular
Cohort (MDC-CC). Of 4195 participants, 577 (13.75%) indivi-
duals developed T2D during a mean (±SD) follow-up time of
19.07 (±5.09) years (Table 1, Supplementary Fig. 1, see Supple-
mentary Information for cohort details). Subjects who developed
T2D during follow-up had higher plasma follistatin levels at
baseline, compared to those who did not progress to diabetes
(Table 1). Circulating follistatin associated with an elevated risk of
diabetes, hazard ratio (HR) per 1-SD increase in follistatin levels
for T2D is 1.29 (CI: 1.19–1.40, p < 0.001), adjusted for age and
sex; and 1.24 (CI: 1.04–1.47, p < 0.05) adjusted for multiple risk
factors (Table 2). When subjects were divided into quartiles (Q)
based on plasma follistatin level, the HRs adjusted for age and sex
for Q4 vs. Q1 for incident diabetes was 1.97 (CI: 1.55–2.50, p for
trend < 0.001); and 1.35 (CI: 1.04–1.74, p for trend = 0.02)
adjusted for multiple risk factors (Table 2, Supplementary Table 1
and Fig. 1). Plasma follistatin levels correlated with measures of
glucose tolerance, insulin secretion, and insulin sensitivity, before
and after adjustment for multiple risk factors (Supplementary
Table 2). The C-statistics value, which is a measure of the ade-
quacy of fit for the binary outcomes, for model 1 adjusted for age
and sex, was 0.5419 (CI: 0.5184–0.5655) and increased sig-
nificantly to 0.5832 (CI: 0.5603–0.6060) when follistatin was
added to the model (difference in C-statistics, 0.041; CI:
0.0187–0.0637; p < 0.001). The C-statistics value adjusted for
multiple risk factors was 0.7701 (CI: 0.7510–0.7892) and
increased to 0.7718 (CI: 0.7527–0.7909), when follistatin was
added (difference in C-statistics, 0.0017; p= 0.113), which may
suggest that follistatin does not improve diabetes prediction on its
own beyond established risk factors.
We also analyzed an independent cohort, IMI-DIRECT-
METSIM (see Supplementary Information for cohort details).
Among 1079 subjects, 53 (4.91%) developed T2D during the
follow-up period (4-year). Individuals with diabetes incidence
had higher baseline plasma follistatin levels (Table 3). The HRs
per SD of plasma follistatin for diabetes was 1.35 (CI: 1.13–1.61,
Table 1 Baseline characteristics of MDC-CC study population (n= 4195).
Whole study population No incident diabetes Incident diabetes p value a
Number (n) 4195 3618 577 –
Follistatin (NPX)† 26.91 ± 1.43 26.54 ± 1.42 28.84 ± 1.44 <0.001
Age (years) 57.33 ± 5.97 57.35 ± 6.01 57.24 ± 5.70 0.696
Sex (men) n (%) 1614 (38.5) 1370 (37.9) 244 (42.3) 0.043
Waist circumference (cm) 82.35 ± 12.14 81.51 ± 11.70 87.63 ± 13.45 <0.001
BMI (kg/m2) 25.41 ± 3.70 25.15 ± 3.49 27.05 ± 4.49 <0.001
HDL (mmol/L) 1.41 ± 0.37 1.42 ± 0.37 1.30 ± 0.34 <0.001
LDL (mmol/L) 4.17 ± 0.98 4.14 ± 0.97 4.34 ± 1.01 <0.001
TG (mmol/L) 1.27 ± 0.60 1.23 ± 0.57 1.51 ± 0.70 <0.001
CRP (mg/L)* 1.30 (0.60-2.60) 1.20 (0.60-2.50) 1.70 (0.90-3.50) <0.001
Systolic blood pressure (mmHg) 140.10 ± 18.60 139.31 ± 18.42 145.11 ± 18.98 <0.001
BP lowering medication n (%) 601 (14.3) 462 (12.8) 139 (24.1) <0.001
Lipid lowering medication n (%) 87 (2.1) 68 (1.9) 19 (3.3) 0.027
Smoking habits n (%) 0.343
Never smokers 1724 (41.1) 1497 (41.4) 227 (39.3)
Ex-smokers 1563 (37.3) 1344 (37.1) 219 (38.0)
Current smokers 908 (21.6) 777 (21.5) 131 (22.7)
Values expressed are means (±SD) or percentages unless specified elsewise. aOne-way analysis of variance (continuous variables) and Pearson’s Chi2 (dichotomous variables) for incident diabetes
(yes/no). *Median [25–75%]. †Follistatin is expressed as linear Normalized Protein eXpression (NPX) AU for relative quantification according to Olink guidance.
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p < 0.01) adjusted for age, and 1.31 (CI: 1.09–1.58, p < 0.01)
adjusted for multiple risk factors (Table 4).
Thus, our findings in longitudinal cohorts indicate that
circulating follistatin associates with the risk of developing T2D.
Relationships of follistatin with adipose tissue insulin resis-
tance and related traits. In the MDC-CC cohort, we observed an
association between the elevated follistatin and insulin resistance
(Supplementary Table 2). In animals follistatin was found to
contribute to diabetes by promoting adipose tissue insulin resis-
tance and attenuating insulin-inhibited white adipose tissue
lipolysis, resulting in increased circulating levels of free fatty acids
(FFAs)15. Here we investigated relationships of circulating fol-
listatin with adipose tissue insulin resistance and related traits in
humans. In subjects of the Tübingen Diabetes Family Study
(TDFS) cohort without diabetes (n= 210, see Supplementary
Information for cohort details), plasma follistatin levels correlated
positively with FFAs, measured before and during the OGTT, and
visceral fat mass. Importantly, the relationships of plasma follis-
tatin with fasting (std. ß= 0.17, p= 0.009), 60 minutes (std.
ß= 0.26, p < 0.0001), and 120 minutes (std. ß= 0.27, p < 0.0001)
FFAs were independent of age, sex, and total body fat mass.
Furthermore, plasma follistatin levels correlated negatively with
adipose tissue insulin sensitivity and leg fat mass (Supplementary
Tables 4, 5 and Fig. 2a). Elevated follistatin levels also associated
with higher liver fat content, after adjustment for age, sex, and
total body fat mass. Furthermore, circulating follistatin levels,
adjusted for age, sex, and total body fat mass, were found to be
elevated in patients with nonalcoholic fatty liver disease (NAFLD,
Fig. 2b). The relationship of follistatin levels with liver fat content
disappeared after further adjustment for visceral fat mass and leg
fat mass, or for adipose tissue insulin sensitivity (Supplementary
Table 6). Thus, these findings suggest that circulating follistatin
independently associates with adipose tissue insulin resistance in
humans, and that the relationship of follistatin with fatty liver is
possibly explained by effects of follistatin on insulin sensitivity of
adipose tissue in the leg and the visceral compartment.
Effect of follistatin on insulin-mediated suppression of lipo-
lysis in adipocytes. The effect of follistatin on insulin-mediated
suppression of lipolysis was investigated in vitro. Human
adipocyte-derived stem cells were differentiated into adipocytes,
and treated with 0, 0.3, 3, or 30 µg/mL follistatin for 2 h before
exposure to insulin for 3 h. Insulin-inhibited lipolysis was atte-
nuated by follistatin dose-dependently, measured by stepwise
increase of glycerol release, reflecting FFA release from adipocytes
into the culture medium from the breakdown of stored trigly-
cerides (Fig. 2c).
GWAS for plasma follistatin levels. To identify causative factors
that influence plasma follistatin levels, we performed GWAS
within the MDC-CC cohort (n= 4239). We identified 13 single-
nucleotide polymorphisms (SNPs), which significantly (p < 5E-8)
associated with plasma follistatin levels (Fig. 3a and b; Supple-
mentary Table 7). The strongest association was observed for a
noncoding SNP rs780094 in the glucokinase regulatory protein
(GCKR) gene (p= 1.1E-11). Two additional SNPs within the
GCKR gene, rs780093 (noncoding) and rs1260326 (coding), in
linkage disequilibrium (LD) with rs78009416, also showed strong
association with plasma follistatin levels, after adjustment for age
and sex (p= 1.91E-11 and p= 2.77E-11; Supplementary Table 7).
Other SNPs displaying associations with plasma follistatin, are
shown in Supplementary Table 7 and Supplementary Fig. 2. The
association between SNPs in the GCKR gene and plasma follis-
tatin was replicated in an independent SUMMIT-VIP cohort
(n= 885, see Supplementary Information for cohort details),
where GCKR rs1260326 showed the strongest association with
Table 2 Incidence of diabetes in relation to sex-specific quartiles of plasma follistatin levels in MDC-CC.
Q1 Q2 Q3 Q4 p for trend HR per SD
Number of participants 1048 1049 1050 1048
Incidence of diabetes n (n per
1000 p-y)
108 (5.16) 132 (6.54) 149 (7.52) 188 (9.87)
Follistatin (NPX)† 17.27 ± 1.21 23.92 ± 1.07 30.06 ± 1.08 42.22 ± 1.23
Model 1 HR 1 1.28 (0.99–1.66) 1.47** (1.15–1.89) 1.97*** (1.55–2.50) <0.001 1.29*** (1.19–1.40)
Model 2 HR 1 1.12 (0.86–1.45) 1.21 (0.94–1.57) 1.45** (1.13–1.86) 0.003 1.31** (1.11–1.56)
Model 3 HR 1 1.10 (0.85–1.43) 1.16 (0.89–1.50) 1.35* (1.04–1.74) 0.020 1.24* (1.04–1.47)
Model 1: Adjusted for age and sex (n= 4195). Model 2: Adjusted for age, sex, BMI, physical activity, alcohol intake, fiber intake, smoking habits, use of antihypertensive medications, systolic blood
pressure, LDL, HDL cholesterol, use of lipid lowering medications, fasting glucose (n= 4060). Model 3: Model 2 and CRP (n= 4060). The relationship between follistatin levels in plasma and incidence
of diabetes during the follow up was explored in 4195 individuals, and fully-adjusted association study was performed in 4060 individuals. HR, hazard ratio. *p < 0.05, **p < 0.01, ***p < 0.001. †Follistatin
is expressed as linear Normalized Protein eXpression (NPX) AU for relative quantification according to Olink guidance.
Number at risk:     
Q1 1048 1028 981 911 773 
Q2 1049 1025 964 856 729 
Q3 1050 1025 951 836 690 
256597429100184014Q
Fig. 1 Kaplan–Meier curve to illustrate incidence of diabetes in relation to
follistatin quartiles. Time axis was follow-up time until death, emigration,
incident diabetes or end of follow-up (n= 4195; p= 1.01E-7; two-sided log-
rank test).
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follistatin levels (p= 2.5E-10, Fig. 3c–d; Supplementary Table 8).
The variant rs780094 in the GCKR gene was found to associate
with diabetes in the DIAGRAM GWAS consortium, both in the
European (OR, 1.04; 95% CI: 1.00–1.08, p= 0.025) and in
transethnic cohorts (p= 1 × 10−5)17.
Regulation of follistatin secretion in the human hepatocyte cell
line HEPG2 BY GCKR. It has been previously shown that the
liver is the major site of follistatin secretion and that follistatin
release from the liver is increased by glucagon and inhibited by
insulin13. Here we studied how GCKR regulates liver follistatin
secretion in the human hepatocyte cell line HepG2. GCKR forms
a tight complex with GCK in the nucleus, and dissociation of the
GCK-GCKR binding leads to increased GCK translocation from
the nucleus to the cytoplasm, which regulates liver cell glucose
uptake and glycolysis18–20. Furthermore, GCKR rs1260326
(p.P446L) has a decreased degree of nuclear localization, enabling
to sequester GCK and to directly interact with GCK, which ele-
vates hepatic glucose uptake and disposal, by increasing active
cytosolic GCK19. Here we applied GCKR-GCK transfection in
combination with a chemical disruptor AMG-3969, to model the
proposed effects for the functional SNPs that we identified in
GWAS, i.e., effects on GCKR-GCK binding and GCKR
expression.
HepG2 cells were transfected with GCK or co-transfected with
GCK and GCKR expressing plasmids (Supplementary Fig. 3).
Forty-eight hours after transfection, the cells were treated with
and without AMG-3669, a GCK-GCKR complex disruptor that
promotes translocation of disassociated GCK from the nucleus to
the cytoplasm21. The addition of AMG-3969 induced GCK
translocation and produced a similar localization pattern to that
of free GCK. The nuclear localization of GCK was highest in the
absence of the disruptor (Supplementary Figs. 4, 5). In the
presence of the GCK-GCKR complex and the complex disruptor
AMG-3969, glucagon increased follistatin secretion by 40%,
compared to control (Fig. 4a). This increase was inhibited by
insulin (Fig. 4b). Transfection with GCK alone, or GCK-GCKR
co-transfection without AMG-3969, had no effect on follistatin
secretion. Thus, our results support the notion that follistatin
secretion is regulated by GCKR in addition to insulin and
glucagon.
Discussion
In this study, we observed that plasma follistatin levels were
elevated many years prior to the onset of T2D, and that circu-
lating follistatin at baseline associated with incident T2D, inde-
pendently of established diabetes risk markers. We also found
that follistatin associated with adipose tissue insulin resistance
and related traits, and that follistatin attenuated insulin-mediated
suppression of lipolysis in adipocytes. Furthermore, we per-
formed GWAS and identified variants in the GCKR to be the
Table 3 Baseline characteristics of non-diabetic individuals (n= 1079) in the IMI-DIRECT-METSIM cohort (Kuopio, Finland).
No incident diabetes Incident diabetes p valuea
Number 1026 53
Follistatin (NPX) 3991.1 ± 1259.73 4329.25 ± 1809.51 0.063
Age (years) 60.97 ± 5.53 60.66 ± 5.78 0.70
Sex (men) n (%) 1026 (100) 53 (100)
BMI (kg/m2) 27.63 ± 3.6 30.19 ± 5.07 8.92E-07
C-peptide (pmol/L) 812.6 ± 302.24 1021.89 ± 428.06 1.80E-06
Glucose (mg/dL) 102.82 ± 7.87 113.33 ± 8.75 2.53E-20
Glucose 48-month (mg/dL) 107.28 ± 8.35 130.31 ± 3.77 8.74E-76
Glucose increase (mg/dL) 4.45 ± 7.69 16.98 ± 8.72 6.42E-29
HbA1c (%) 5.53 ± 0.27 5.61 ± 0.31 0.033
HDL (mg/dL) 53.82 ± 14.57 49.79 ± 11.52 0.048
LDL (mg/dL) 117.25 ± 33.79 119.35 ± 29.35 0.66
TG (mg/dL) 122.06 ± 60.15 142.45 ± 54.39 0.016
CRP (mg/L) 1.82 ± 3.58 2.26 ± 2.73 0.37
Values expressed are means (±SD) or percentages unless specified elsewise. aOne-way analysis of variance (continuous variables) and Pearson’s Chi2 (dichotomous variables) for incident diabetes
(yes/no). CRP C-reactive protein.
Table 4 Incidence of diabetes in relation to quartiles of follistatin in the IMI-DIRECT-METSIM cohort. The relationship between
follistatin levels in plasma and incidence of diabetes during the follow up was explored in 1079 individuals, and fully-adjusted
association study was performed in 883 individuals.
Q1 Q2 Q3 Q4 p for trend HR per SD
Number of participants 270 270 269 270
Incidence of diabetes n (n per
1000 p-y)
10 (9.26) 13 (12.04) 11 (10.22) 19 (17.59)
Follistatin (NPX) 2664.94 ± 343.49 3447.24 ± 205.82 4194.21 ± 258.59 5725.14 ± 1163.54
Model 1 HR 1 1.69 (0.80–3.58) 1.49 (0.70–3.22) 2.61** (1.29–5.30) 0.011 1.35** (1.13–1.61)
Model 2 HR 1 1.12 (0.48–2.60) 1.19 (0.52–2.75) 2.25* (1.04–4.86) 0.029 1.28**
(1.075–1.524)
Model 3 HR 1 1.13 (0.49–2.62) 1.23 (0.53–2.86) 2.34* (1.07–5.101) 0.0237 1.31** (1.09–1.58)
Model 1: Adjusted for age (n= 1079).
Model 2: Adjusted for age, BMI, physical activity, alcohol intake, fiber intake, LDL, HDL cholesterol, fasting glucose (n= 883).
Model 3: Model 2 and CRP (n= 883).
HR hazard ratio. *p < 0.05, **p < 0.01
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genetic regulators of circulating follistatin levels (summarized in
Fig. 5).
In the MDC-CC cohort, elevated plasma follistatin levels
associated with the incidence of diabetes up to 19 years before the
onset of the disease. While it is important that this association was
found during a long period of follow-up, parameters other than
elevated follistatin levels, which may become relevant just prior to
the onset of diabetes, or also associate with elevated follistatin
levels, may contribute to this relationship. Therefore, we analyzed
an independent IMI-DIRECT-METSIM cohort, with 4-year fol-
low-up. The independent association between the elevated follis-
tatin and an increased risk of diabetes was also confirmed in this
shorter follow-up period. We also included fasting glucose and
CRP to the models to ensure that factors in the subclinical phase
of diabetes development were not responsible for the raised levels
of follistatin. These data suggest that increased circulating follis-
tatin may serve as a marker of diabetes risk, which may be relevant
to indicate an increased risk of diabetes, up to 19 years prior to the
manifestation of the disease. However, it is worth noting that our
C-statistics analysis also suggests that follistatin on its own may
not improve diabetes prediction beyond established risk factors.
Previous investigations have presented rather contradictory
evidence on the effects of follistatin under physiological and
pathophysiological conditions13–15. Nevertheless, the physiologi-
cal regulation of follistatin secretion and pathological effects of
abnormally elevated follistatin may represent different avenues.
Under normal physiological conditions, disruption of the GCKR-
GCK complex, triggered by e.g., glucose and fructose22, stimulates
follistatin secretion, which is regulated by insulin and glucagon.
However, in an insulin-resistant state, attenuated insulin signal-
ing in the liver may lead to elevated follistatin secretion as pre-
viously shown in mouse models15. Abnormally elevated follistatin
secretion may further exacerbate liver insulin resistance by pro-
moting FFA production from adipose tissue and ultimately lead
to NAFLD, possibly aggravating diabetes. The previous finding
that follistatin increases beta-cell proliferation during normal
physiological conditions13 is perfectly in line with the need for
increased insulin secretion to compensate for insulin resistance,
and furthermore raises the intriguing possibility that follistatin
plays a key role in mediating this signal from the liver to the
pancreatic beta cell. Further studies are needed to understand the
role of follistatin in the cross-talk between liver and pancreas in
normal, as well as pathophysiological conditions.
After investigating mechanisms by which follistatin may be
involved in the pathophysiology of T2D, our data suggest that the
effect of follistatin in promoting adipose tissue insulin resistance
in mice15 may also be operative in humans. We found that cir-
culating follistatin correlated negatively with adipose tissue
insulin sensitivity and positively with circulating FFA levels and
liver fat content. Interestingly, the relationship of follistatin with
liver fat was affected by adjustment for the percentage of leg fat
mass, which suggests that follistatin may impair insulin sensitivity
of adipose tissue, predominantly in leg fat, the fat compartment



























Fig. 2 Association of follistatin with adipose tissue insulin resistance and nonalcoholic fatty liver disease (NAFLD). a Relationship of adipose tissue
insulin sensitivity, adjusted for age, sex, and total body fat mass, with follistatin levels, in a multivariate linear regression model in the Tübingen Diabetes
Family Study (TDFS) cohort (n= 210). Depicted is the regression line and the 95% CIs. b Relationship of follistatin levels, adjusted for age, sex, and total
body fat mass, with NAFLD, in a multivariate logistic regression model (TDFS, n= 210). c Human adipose-derived stem cells (Lonza) were differentiated
into adipocytes (see details in Methods). Cells were maintained in insulin-free media overnight and treated with 0, 0.3, 3, and 30 µg/mL follistatin for 2 h
followed by addition of 100 ng/mL insulin for 3 h. Breakdown of triglyceride released glycerol and free fatty acids (FFAs), and lipolysis was determined by
measuring media glycerol content. Three independent experiments (n= 3) were performed. Statistical significance was determined by Tukey–Kramer HSD
using JMP 14.1.0. ***p < 0.001 as indicated.
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Fig. 3 GWAS of follistatin in the MDC-CC and SUMMIT-VIP cohort. a Manhattan plot (−log10 GWAS plot) of GWAS on plasma follistatin in individuals
of MDC-CC cohort (n= 4195). The most significant SNPs in this analysis are rs780094, rs780093, and rs1260326 in the GCKR gene (glucokinase
regulatory protein). b Quantile-quantile (QQ) plot of the data shown in the Manhattan plot in a. cManhattan plot (−log10 GWAS plot) of GWAS on plasma
follistatin in individuals of SUMMIT cohort (n= 885). The most significant SNP in this analysis is rs1260326 in the GCKR gene. d Quantile-quantile (QQ)
plot of the data shown in the Manhattan plot in c. The genome-wide significance level is set at 5 × 10−8 and plotted as the dotted line.
Fig. 4 Liver cell follistatin secretion is controlled by the glucokinase regulatory protein- glucokinase (GCKR-GCK) complex. a Human liver carcinoma-
derived HepG2 cells were transfected with plasmids as indicated: (i) control (pCMV-XL4, grey round plots); (ii) GCK:GCKR (1:0; no GCKR, orange square
plots); (iii) GCK:GCKR (1:3, blue triangle plots). Forty-eight hours after transfection, cells were serum starved in 5.5 mM DMEM for 3 h, and a GCKR-GCK
disruptor molecule AMG-3969 (0.7 μM) was added in the medium for 30min. Cells were then incubated in serum-free low glucose (5.5 mM) DMEM
containing glucagon (0.3 µM) and forskolin (20 µM), and AMG-3969 (0.7 μM) was added to respective wells. After 4-hour incubation, the medium was
collected for follistatin assay by ELISA. Follistatin levels were normalized to the protein concentration within each sample. b HepG2 cells were treated as
described in panel a, but in the presence of insulin (100mM). Two independent experiments with 3 technical replicates per condition were performed in
different days using different plasmid preparations and cell passage numbers (n= 6; *p= 0.03 and **p= 0.005; ANCOVA with “experiment” as covariable
and LSD post-hoc test; data are presented as mean values+ /− SD).
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this respect, it is important to note that in our study adipose
tissue insulin sensitivity correlated positively with the percentage
of leg fat mass, but negatively with visceral fat mass. Conse-
quently, it could be speculated that follistatin-induced adipose
tissue insulin resistance shifts fatty acids not only to the visceral
fat depots, but also to the liver and, thereby, aggravates NAFLD.
This view was further supported by our in vitro adipocyte data
that excess follistatin attenuated insulin-inhibited lipolysis and
elevated FFA release, which in turn may predispose to NAFLD.
Increased FFAs per se also stimulate glycogenolysis, gluconeo-
genesis and, thereby, contribute to increased risk of T2D25.
However, it is not fully understood how follistatin regulates
lipolysis in adipocytes. It has been shown in a previous investi-
gation in mice that follistatin suppresses the interaction between
insulin receptor substrate 1 (Irs1) and p110a subunit of PI3-
kinase in adipose tissue of LDKO mice, which was consistent with
reduced AKT activation, attenuated phosphorylation, and inac-
tivation of hormone-sensitive lipase (HSL)15. The exact
mechanisms by which follistatin inhibits the association between
Irs1 and p110a requires further investigation. Furthermore, in our
in vitro experiments on human adipocytes, the concentrations of
follistatin were relatively higher than those in the serum of
healthy subjects during an overnight fast. Nevertheless, it has also
been shown that serum follistatin levels may vary considerably in
different situations, such as pregnancy and in various disease
states26, as well as under a mixed meal test, exercise, and pro-
longed fasting26–28. We may speculate that under certain condi-
tions higher follistatin concentrations may also be present in vivo.
Besides our previous and present findings on the impact of fol-
listatin on the regulation of glucose and lipid metabolism in animals
and in vitro, to further investigate causal relationships of follistatin
with an incidence of diabetes, Mendelian randomization (MR) ana-
lysis would be an instrumental approach. Using variants of GCKR in
MR analysis, which we identified to be most strongly associated with
follistatin levels, is nevertheless very problematic, because these var-
iants of GCKR were found to be the most pleiotropic variants in our
exome sequencing study of close to 10,000 individuals (unpublished
data in the DIRECT-METSIM study). In this respect, the variant
rs780094 in GCKR, which most strongly associated with follistatin
levels in our study, was found to associate with elevated fasting and
random glycemia and increased risk of T2D in several large studies.
However, it also strongly associated with lower CRP, triglyceride,
LDL cholesterol levels, and other diabetes risk parameters (https://
t2d.hugeamp.org/variant.html?variant=rs780094).
Our GWAS analyses in two independent cohorts identified the
SNP rs1260326 in the GCKR gene to strongly associate with
plasma follistatin levels. This SNP has also been shown in pre-
vious studies to be associated with more than 25 metabolic traits,
including T2D risk, NAFLD, fasting insulin, total cholesterol, as
well as circulating levels of various metabolites29. It is noteworthy
that functional variants in the GCKR gene have been associated
with opposite effects on fasting plasma triglyceride and glucose
concentrations16. Experiments in diabetic animals also showed
that the small molecule disruptor of the GCKR-GCK complex
AMG-1694 lowered blood glucose, but increased triglyceride
levels21. Based on our findings, this phenomenon may now be
explained by the fact that the GCKR-GCK disruptor may have
increased liver cell follistatin secretion, which in turn, may have
promoted adipose tissue insulin resistance and an increase of
triglyceride levels.
The molecular mechanisms by which the GCK-GCKR system
regulates follistatin secretion in hepatic cells is not known. GCKR
regulates GCK, playing an important role in regulating the rate of
glucose metabolism in the hepatocyte. Thus, we can hypothesize
that the association of GCKR locus with follistatin levels may be
explained by the effects of GCKR regulatory SNPs on GCKR
function in the liver. To examine how GCKR-GCK may regulate
the secretion of follistatin from the liver, we employed in vitro
experiments in the human hepatocyte cell line HepG2. Although
the HepG2 cell line shows altered metabolic activity compared to
primary hepatocytes, the cell line serves as an acceptable model to
study how GCKR-GCK nuclear dissociation and GCK translo-
cation to the cytoplasm regulate follistatin secretion. Transfection
of GCK alone did not increase follistatin secretion in HepG2 cells.
This may be explained by the very low endogenous expression of
GCKR in HepG2 cells, in the absence of which GCK is decreased,
likely through degradation30–32.
In the liver, GCK facilitates the storage of glucose as glycogen,
which is under the control of GCKR via binding and subsequently
inactivation of GCK in the nucleus of the hepatocyte. Disruption
of the GCKR–GCK complex enables the translocation of GCK
from the nucleus to the cytoplasm where it facilitates the con-
version of glucose to glucose-6-P33. In the postprandial state with
increased glucose levels, GCKR-GCK complex is disrupted and
GCK is released to the cytoplasm where it stimulates glycolysis,
glycogen formation, and de novo lipogenesis, while in the fasting
state, GCKR suppresses GCK and subsequently hepatic glycolysis.
Notably, we provide a mechanism linking glucagon- and insulin-
regulated follistatin secretion to GCKR. Here we observed that
glucagon was only capable of stimulating follistatin secretion
from the liver cells upon GCKR-GCK disruption. This may
induce a vicious cycle in that both the high glucose and high
glucagon, increase follistatin secretion, resulting in increased
adipose tissue lipolysis and circulating FFAs. Furthermore, we
also observed that insulin suppresses follistatin secretion inde-
pendently of glucagon-GCK-GCKR signaling. Nevertheless, as
Fig. 5 Schematic illustration of crosstalk between liver follistatin
production and adipocyte insulin-inhibited lipolysis. Liver follistatin (FST)
secretion is regulated by GCKR-GCK, which is stimulated by glucagon and
inhibited by insulin. Elevated follistatin may attenuate insulin-inhibited
lipolysis in the adipocytes and mediate adipose tissue insulin resistance and
free fatty acid (FFA) release, which ultimately contributes to T2D and
NAFLD risk.
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the GCKR variants are associated with multiple molecular traits,
including multiple other protein markers, at this stage, we do not
know if the malfunction of GCKR is peculiar to follistatin, or if
other proteins are involved.
The GCKR gene is in close proximity to ZNF512, C2orfl6, and
GPN1 on chromosome 2, which also contains SNPs showing sig-
nificant association with plasma follistatin levels. Other SNPs
showing significant association with plasma follistatin include
exm1435650 in the ZNF333 gene (p= 1.98E-11), exm831645 in
ADAMTS14 (p= 5.50E-11), exm373967 in TEME44 (p= 2.05E-
09) and exm646262 in CUX1 which have been shown to be genetic
factors influencing elevated markers of death receptor-activated
apoptosis associated with increased diabetes and cardiovascular
disease risks34. The effect of these identified genes strongly asso-
ciated with circulating follistatin requires further investigation.
In conclusion, elevated circulating follistatin associates with an
increased risk of incident T2D, independently of established diabetes
risk markers. Among the mechanisms that may explain this rela-
tionship in humans we found supporting evidence that follistatin
induces insulin resistance in adipose tissue, thereby, promoting
adipose tissue lipolysis and NAFLD. Furthermore, we found that the
GCK-GCKR complex may be involved in the regulation of plasma
follistatin levels in humans. Thus, follistatin may be an attractive
target for therapeutic interventions to prevent T2D and NAFLD.
Methods
Study cohorts and biomarker measurements. Detailed description of study
participants, plasma biomarker measurements, phenotyping procedures and
GWAS of the Malmö Diet and Cancer study (MDC-CC); the SUrrogate markers
for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools-
Vascular Imaging Project (SUMMIT-VIP) study cohort; the Innovative Medicines
Initiative Diabetes Research on Patient Stratification (IMI-DIRECT) cohort
including its sub-cohort IMI-DIRECT-METSIM; and the Tübingen Diabetes
Family Study (TDFS) cohort are presented in the Supplementary Information.
Follistatin measurements. Plasma follistatin levels in the MDC-CC, IMI-
DIRECT-METSIM, and SUMMIT-VIP cohorts were assessed by Proximity
Extension Assay (PEA) in the Olink platform (https://www.olink.com), where
different antibody types were validated to ensure reproducible quantifications of
the analyte in biological samples35. This method is based on a matched pair of
antibodies linked to unique oligonucleotides binds to the respective protein target,
and DNA amplicon can be subsequently quantified by quantitative real-time PCR.
Specifically, follistatin was measured using a Proseek Multiplex CVD I 96 × 96 Kit
(Olink Bioscience, Uppsala, Sweden) assay based on the Proximity Extension
Ligation technology on a Fluidigm BioMark HD real-time PCR platform in 54 chip
runs35. The lower and upper limits of follistatin were 1.91 and 62,500 pg/mL,
respectively. The samples were consecutively aliquoted on plates, regardless of
future diabetes status. The plates were analysed in random order. Follistatin con-
centrations are presented as normalized protein expression (NPX) arbitrary units
(AU) with log2 scale calculated from Ct values which was converted into the linear
scale (2NPX= linear NPX). The NPX measurement provides relative qualification,
and samples can be compared within a cohort but not in two separate cohort
studies with different scales as seen in MDC-CC and IMI-DIRECT-METSIM
cohorts, where epidemiological findings based on follistatin measurements were
robustly reproduced independently. Furthermore, the PEA offers highly specific
and sensitive large-scale measurement and has been shown to be comparable to
ELISA method36. The intra-assay coefficient of variation (CV) was 9%, and the
inter-assay CV was 15%. CV was calculated per assay using the assumption of a
log-normal distribution. The CV was then averaged across panels (www.olink.com
for details). For smaller sample size in the TDFS cohort, follistatin was measured by




In MDC-CC, non-fasting blood samples were drawn at the baseline examination and
stored in the biobank at −80 °C. All individuals with information on follistatin plasma
levels and genotypes (n= 4239) were included. Genotyping was performed using the
Illumina HumanOmniExpressExome Bead Chip on the iScan system and using the
Autocall calling algorithm (Illumina, San Diego, CA, USA). For GWAS, we included all
individuals with information on follistatin plasma levels and genotypes (n= 4239).
Quality control was performed by exclusion of missingness > 0.05 (both individual and
genotypic); identity-by-descent (IBD) match; heterozygosity (absolute cryptic relatedness
inbreeding coefficient > 0.2); sex mismatch; population outliers. The minor allele fre-
quency limit was 0.01. A total of 628526 SNPs was included in the analysis.
Linear regression models, with an additive genetic model, were used to test the
association between genetic variants and follistatin levels, with adjustment for age and
sex. A p value < 5 × 10−8 was considered as genome-wide significant, corresponding to a
Bonferroni correction for one million tests. Version 1.07 of PLINK software was used for
association analyses and QC. Manhattan plots and Q-Q plots were drawn with the R
software version 3.1.2. Regional significance plots were drawn using LocusZoom (http://
locuszoom.sph.umich.edu/locuszoom/).
SUMMIT
Raw sequencing data were subjected to quality control and imputation using an array of
well-developed and optimized software before the data analysis started. For quality
control samples were filtered based on individual characteristics; genotyping rate, sex
check, population stratification, identified by descent and heterozygosity and variant
sequencing quality; genotyping rate, Hardy–Weinberg equilibrium, minor allele fre-
quency, and minor allele count. QC Protocols using PLINK produced efficient and
reproducible QC that can be customized to suit different genotype datasets. Quality
control filtering cleaned the data from individuals that can cause errors in the analysis;
duplicated individual samples, first-degree relatives, individuals from different ancestry,
and individuals with low genotyping rate. Rare variants are those single-nucleotide
polymorphisms (SNPs) that deviate significantly from Hardy–Weinberg equilibrium and
can cause false positives.
SUMMIT dataset was imputed by HRC Michigan Imputation Server. Haplotype Refer-
ence Consortium (HRC) is a large reference panels that has 64970 human haplotypes and
39,235,157 snps from 20 cohorts mainly from European ancestry. HRC server offers an
imputation platform for genotype data. Genotype data that passed quality control were
separated to chromosome files, each file has the SNPs of a single chromosome to be
imputed and they are usually in VCF format. The imputed chromosome files along with
a quality report were downloaded from the server.
GWAS was performed for the HRC imputed SUMMIT dataset using SNPTEST (snptest
version 2.5.2). The SNPTEST output was filtered for the minor allele frequency
(MAF > 0.05), INFO score (> 0.4), and Hardy–Weinberg equilibrium (HWE >
0.0000057). Manhattan plots and Q-Q plots were generated in R (R version 3.4.3).
Human adipocyte differentiation and lipolysis measurement. Human adipose-
derived stem cells were obtained from Lonza and seeded in 96-well plates (160,000
cells/cm2) in 100 µL EGM2-MV medium (Zenbio). After 24 h, the medium was
replaced with PM1 (Zenbio) for 24 h, followed by initiation of differentiation with
DM2 (Zenbio) medium for 6 days. Subsequently, the cells were maintained in AM1
(Zenbio) every 3-days until assays were performed. Differentiated adipocytes were
utilized between days 12 and 14 postinitiation of differentiation. For lipolysis
assays, differentiated adipocytes were maintained in insulin-free medium (PM1)
overnight and treated in DMEM (11054-020, Gibco) containing 0.2% fatty acid-
free BSA (03117057001, Roche) with 0, 0.3, 3, or 30 µg/mL follistatin (120-13,
PeproTech) for 2 h followed by addition of 100 ng/mL insulin (SLBX8532, Sigma)
for 3 h. Lipolysis was determined by measuring media glycerol content (F6428,
Sigma). Data were plotted using GraphPad Prism and significance was determined
using Dunnett’s Test in JMP.
Follistatin secretion in HEPG2 cells. Human liver carcinoma-derived HepG2
cells (ATCC, HB-8065) were cultured in 5.5 mM Dulbecco’s modified Eagle
medium (DMEM) supplemented with 2 mM L-glutamine, 100 U/ml peni-
cillin,100 μg/ml streptomycin (LONZA), and 10% fetal bovine serum (GIBCO).
Cells were seeded on 24 well plates and incubated overnight at 37 °C in 5% CO2,
and then transfected with plasmids using lipofectamine 3000 according to man-
ufacturer´s instructions (Thermo Fisher Scientific). Forty-eight hours after trans-
fection, cells were serum starved in 5.5 mM DMEM for 3 h and AMG-3969
(0.7 μM, MCE) was added for 30 min. Next, cells were incubated with or without
insulin (100 mM) together with glucagon (0.3 µM) and intracellular cAMP acti-
vator forskolin (20 μM) in low glucose DMEM medium (5.5 mM), conditions
previously shown to stimulate follistatin secretion in liver cells13. AMG-3969 was
added to respective wells. Media was collected after 4 h and diluted (1:2) for fol-
listatin ELISA assay (DFN00, R&D Systems) according to manufacturer’s
instructions.
Statistics. In MDC-CC and IMI-DIRECT-METSIM analyses, one-way analysis of
variance for continuous variables and Pearson’s Chi-squared test for dichotomous
variables were used to assess the cross-sectional relationships between plasma
follistatin quartiles and diabetes risk factors. Multiple linear regression was used to
analyze the association between follistatin and glucose, HbA1c, HOMA2, and
insulin at baseline and reexamination, adjusted for potential confounding factors.
Natural log-transformed values for HOMA2, insulin and CRP were used due to
skewed distributions.
Cox proportional hazards regression was used to examine hazard ratios (HR)
with 95% confidence interval (CI) for incidence of diabetes, by quartiles of
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follistatin and per 1 standard deviation (SD) increment, using the lowest quartile as
the reference category. Potential confounders were age, sex, waist circumference,
smoking habits, LDL, HDL cholesterol, fasting glucose, systolic blood pressure,
antihypertensive medications, lipid-lowering medications, CRP, BMI, physical
activity, alcohol intake, and fiber intake. The fit of the proportional hazards model
was confirmed by plotting the incidence rate over time. The Kaplan–Meier curve
was used to illustrate the incidence of diabetes in relation to the follistatin quartiles.
Time axis was follow-up time until death, emigration, incident diabetes or end of
follow-up. SPSS Statistics (version 22) and Stata software version 12.0 (Stata Corp,
College Station, TX, USA) were used for statistical analyses.
In TDFS cohort analysis data are given as mean ± SD. For statistical analyses
data that were not normally distributed (Shapiro-Wilk W Test) were inverse
normal transformed to achieve a normal distribution for the investigation of
univariate and multivariate relationships. Pearson correlation and the
nonparametric Wilcoxon test were used to investigate univariate relationships
between the parameters. Multivariate models were used to investigate independent
relationships. The statistical software package JMP 13.0.0 (SAS Institute Inc, Cary,
North Carolina) was used.
Ethics. The study was performed in accordance with the Declaration of Helsinki.
The ethics committee at Lund University approved the MDC; and SUMMIT study
was approved by ethics committees in each of the centers in Malmö (Sweden), Pisa
(Italy), Dundee (U.K.), and Exeter (U.K.). For DIRECT-METSIM cohort, approval
for the study protocol was obtained from the Ethics Committee of the University of
Eastern Finland and Kuopio University Hospital and all participants provided
written informed consent at enrolment. The research conformed to the ethical
principles for medical research involving human participants outlined in the
declaration of Helsinki. For TDFS cohort, informed written consent was obtained
from all participants and the Medical Ethics Committee of the University of
Tübingen had approved the protocol.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All the relevant data supporting the findings of this study are available within this article,
in the supplementary material, the source data file, or relevant repositories. For MDC-
CC, SUMMIT and TDFS cohorts, Swedish, European and German legislation impose
restrictions on public availability of datasets containing pseudonymized information. The
full datasets including genome-wide data and phenotypes can be accessed for the MDC-
CC through an institutional repository at Lund University (https://www.malmo-
kohorter.lu.se/english), and SUMMIT through the SUMMIT vascular imaging project
steering committee (jan.nilsson@med.lu.se), and University of Tübingen
(Norbert.Stefan@med.uni-tuebingen.de) with pertinent permissions. Details on how to
requests access to IMI-DIRECT data, including data presented here, can be found
through https://directdiabetes.org/contacts/. Requestors will be provided with
information and assistance on how data can be accessed via the DIRECT Computerome
following submission of appropriate documentation. Source data are provided with
this paper.
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